Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer
Open Access
- 1 February 2004
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 15 (2), 230-235
- https://doi.org/10.1093/annonc/mdh063
Abstract
Background: For oesophageal cancer there is no effective standard therapy. We studied the feasibility and efficacy of the cisplatin–gemcitabine combination chemotherapy in patients with unresectable oesophageal cancer. Patients and methods: Thirty-six chemonaïve patients with unresectable or metastatic oesophageal adenocarcinoma (24) or squamous-cell-carcinoma (12) were treated with cisplatin (50 mg/m2, days 1 and 8), followed by gemcitabine (800 mg/m2, days 2, 9 and 16), every 28 days. Feasibility and efficacy were studied. Results: Toxicity was substantial but manageable. A median number of four therapy cycles was given. The most frequent grade ≥3 toxicities were leukopenia (75%) and neutropenia (83%). Three patients developed neutropenic fever. Grade 3/4 thrombocytopenia occurred in 24 out of 36 patients (67%), but did not result in serious bleeding disorders. Myelotoxicity was cumulative and required omission of gemcitabine on day 16 in 63% of cycles. Anaemia required treatment with erythropoietin, red blood cells or both in 81% of patients. Non-haematological toxicity consisted mainly of grade 1/2 nausea/vomiting or fatigue. Fourteen out of 34 evaluable patients had a major objective response (41%; two complete and 12 partial responses). The median actuarial survival was 9.8 months. Conclusion: This cisplatin–gemcitabine regimen was feasible, with myelosupression being the main toxicity, and had significant activity in patients with advanced oesophageal cancer.Keywords
This publication has 22 references indexed in Scilit:
- Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junctionAnnals of Oncology, 2000
- Basis for effective combination cancer chemotherapy with antimetabolitesPharmacology & Therapeutics, 2000
- Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal CancerJournal of Clinical Oncology, 1999
- Scheduling of gemcitabine and cisplatin in Lewis Lung tumour bearing miceEuropean Journal Of Cancer, 1999
- Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumorsAnnals of Oncology, 1999
- Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- Chemotherapy in oesophageal cancerCancer Treatment Reviews, 1997
- Comparison of prevalence and resection rates in patients with esophageal squamous cell carcinoma and adenocarcinomaThe Journal of Thoracic and Cardiovascular Surgery, 1996
- Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenograftsEuropean Journal Of Cancer, 1995
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961